Finch Therapeutics Group Performance
| FNCHDelisted Stock | USD 8.51 0.19 2.18% |
The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and Finch Therapeutics are completely uncorrelated. Finch Therapeutics right now shows a risk of 0.0%. Please confirm Finch Therapeutics daily balance of power and price action indicator , to decide if Finch Therapeutics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Finch Therapeutics Group has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong fundamental indicators, Finch Therapeutics is not utilizing all of its potentials. The latest stock price confusion, may contribute to short-horizon losses for the traders. ...more
| Begin Period Cash Flow | 71 M |
Finch |
Finch Therapeutics Relative Risk vs. Return Landscape
If you would invest 851.00 in Finch Therapeutics Group on October 6, 2024 and sell it today you would earn a total of 0.00 from holding Finch Therapeutics Group or generate 0.0% return on investment over 90 days. Finch Therapeutics Group is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Finch, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Finch Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Finch Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Finch Therapeutics Group, and traders can use it to determine the average amount a Finch Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| FNCH |
Based on monthly moving average Finch Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Finch Therapeutics by adding Finch Therapeutics to a well-diversified portfolio.
Finch Therapeutics Fundamentals Growth
Finch Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Finch Therapeutics, and Finch Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Finch Pink Sheet performance.
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 10.74 M | ||||
| Shares Outstanding | 1.61 M | ||||
| Price To Book | 0.14 X | ||||
| Price To Sales | 30.46 X | ||||
| Revenue | 107 K | ||||
| EBITDA | (32.48 M) | ||||
| Cash And Equivalents | 104.67 M | ||||
| Cash Per Share | 2.19 X | ||||
| Total Debt | 30.13 M | ||||
| Debt To Equity | 0.35 % | ||||
| Book Value Per Share | 11.86 X | ||||
| Cash Flow From Operations | (31.5 M) | ||||
| Earnings Per Share | (6.59) X | ||||
| Total Asset | 71 M | ||||
| Retained Earnings | (350.39 M) | ||||
About Finch Therapeutics Performance
By evaluating Finch Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Finch Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Finch Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Finch Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts. Finch Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 189 people.Things to note about Finch Therapeutics performance evaluation
Checking the ongoing alerts about Finch Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Finch Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Finch Therapeutics is not yet fully synchronised with the market data | |
| Finch Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 107 K. Net Loss for the year was (74.75 M) with loss before overhead, payroll, taxes, and interest of (57.03 M). | |
| Finch Therapeutics Group currently holds about 104.67 M in cash with (31.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.19. | |
| Roughly 53.0% of the company shares are held by company insiders |
- Analyzing Finch Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Finch Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Finch Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Finch Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Finch Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Finch Therapeutics' pink sheet. These opinions can provide insight into Finch Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Finch Pink Sheet
If you are still planning to invest in Finch Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Finch Therapeutics' history and understand the potential risks before investing.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |